Supernus Stock Is Up 31% This Past Year but Still 20% Below 2018 Highs as One Fund Scales Back

Aristotle Capital Boston disclosed in a November 14 SEC filing that it sold 503,122 shares of Supernus Pharmaceuticals (NASDAQ:SUPN), contributing to a reduction in its position by about $10.9 million.According to a Securities and Exchange Commission (SEC) filing dated November 14, Aristotle Capital Boston reduced its holdings in Supernus Pharmaceuticals (NASDAQ:SUPN) by 503,122 shares in the third quarter. The fund’s overall position decreased to 305,273 shares with a reported value of $14.6 million as of September 30. The estimated value of shares sold was approximately $10.9 million.Supernus represents about 0.75% of 13F AUM as of September 30.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool